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Comparative eﬀ ect sizes in randomised trials from less 
developed and more developed countries: a meta-
epidemiological assessment
Orestis A Panagiotou, Despina G Contopoulos-Ioannidis, John P A Ioannidis
Abstract
Background Many trials are done in developing countries without a longstanding tradition in research. We compared 
treatment eﬀ ects from randomised trials conducted in developed versus developing countries.
Methods We used data from the Cochrane Database of Systematic Reviews to identify meta-analyses about mortality 
with at least one trial from a developing country and one from a developed country (WHO and International Monetary 
Fund classiﬁ cations). Eﬀ ect estimates of developed and developing countrieswere compared by calculating the relative 
relative risks (RRR) for each topic and the summary RRRs across all topics. Similar analyses were done for the 
respective primary outcomes.
Findings 139 mortality meta-analyses were eligible. 128 (92%) meta-analyses reported no signiﬁ cant diﬀ erences 
between developed and developing countries. Diﬀ erences were beyond chance in 11 (8%) cases showing more 
favourable eﬀ ects in trials from developing countries. The summary RRR was 1·12 (95% CI 1·06–1·18, p<0·0001, 
I2=0%), suggesting signiﬁ cantly increased favourable eﬀ ects in trials from developing countries. Results were similar 
for meta-analyses with signiﬁ cant eﬀ ects for mortality (RRR 1·15, 95% CI 1·08–1·23, p<0·0001), meta-analyses with 
recent trials (1·14, 1·08–1·21, p<0·0001); and when excluding trials from developing countries that became developed 
(1·12, 1·06−1.18, p<0·0001). For the primary outcomes (n=127), 20 topics had signiﬁ cant diﬀ erences in eﬀ ects (more 
favourable in developing countries in 15 cases).
Interpretation Trials from developing countries sometimes show signiﬁ cantly more favourable eﬀ ects than trials 
in developed countries. On average, eﬀ ects are more favourable in developing countries than in developed countries. 
These discrepancies show biases in reporting or study design and genuine diﬀ erences in baseline risk or treatment 
implementation and should be considered when generalising evidence.
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